Kornimate/medical-research-clean huggingface dataset:
clinico-functional evaluation of gerd: comparative study of vertical sleeve gastrectomy vs roux-en-y gastric bypass

Conditions: Gastroesophageal Reflux Disease; Morbid Obesity

Summary: the hypothesis of this study is that surgical techniques primarily designed for weight loss, ameliorates gastroesophageal reflux disease (gerd) in morbidly obese patients. therefore the present study intends to evaluate such impact on patients submitted to two of the most common techniques available, the roux-en-y gastric bypass and vertical sleeve gastrectomy.

in order to determine if weight loss surgeries do indeed ameliorate gerd in morbidly obese patients, esophageal syndromes will be evaluated following the montreal consensus, where troublesome symptoms were defined as score ≥ 2 on a validated questionnaire of symptoms for portuguese language along with esophageal syndromes with injury assessed through upper endoscopy. esophageal acid exposure will be determined through 24h ph monitoring. increased acid exposure will be characterized when total esophageal ph \< 4 for at least 4% of its total monitoring time.

Eligibility criteria:
inclusion criteria: * bmi \> 40 kg/m2, or bmi \> 35 kg/m2 along with clinical comorbidities (such as diabetes mellitus, systemic arterial hypertension or articular lesions) * been unable to loose or sustain weight loss after 2 years medical and nutritional treatments. exclusion criteria: * been previously submitted to any gastroesophageal surgical procedure * presence of chronical diseases that affects esophageal motility * do not tolerate any of the required exams

Keywords: gerd roux-en-y gastric bypass vertical sleeve gastrectomy
fecal calprotectin in patients infected with intestinal protozoan infections

Conditions: Fecal Calprotectin in Intestinal Protozoa

Summary: calprotectin extracted from stool can be detected easily using elisa. numerous studies have shown that fecal calprotectin concentrations demonstrate a good correlation with intestinal inflammation this study aims to detect the relationship between fecal calprotectin and blastocystis hominis and entamoeba histolytica infections.


Eligibility criteria:
inclusion criteria: 120 fecal samples will be collected as the following: * 40 samples from patients complaining of gastrointestinal manifestations and only infected with b.hominis and e.histolytica. * 40 samples from patients complaining of gastrointestinal manifestations without any protozoal infection. * 40 healthy control cross-matched volunteers (without gastrointestinal manifestations, or intestinal parasites). exclusion criteria: * persons received antiparasitic drugs or antibiotic 2 weeks before sample collection patients with mixed intestinal protozoa patients with intestinal protozoa rather than entamoeba histolytica and blastocystis
evaluating the effect of bathing additives in atopic dermatitis

Conditions: Atopic Dermatitis; Eczema

Summary: this proposed project will be an open-label, split-arm, randomized controlled pilot study. up to 60 patients diagnosed with atopic dermatitis (eczema) will be enrolled in the study. the purpose of this study is to understand the change in skin barrier function and skin microbial composition in patients with atopic dermatitis following dilute bleach bath/soak and dilute vinegar bath/soak.

atopic dermatitis (ad), also known as eczema, is an inflammatory skin condition that affects children and adults and causes skin redness, dryness and itching. dilute bleach baths are standard of care for treatment of ad and work to decrease skin inflammation and modulate the skin microbiome. dilute vinegar (acetic acid) has been reported to have similar effects on the skin. the purpose of this study is to evaluate the change in skin barrier function and skin microbial composition following baths or gauze soaks with dilute bleach and dilute vinegar.

Eligibility criteria:
inclusion criteria: * males and females, at least 5 years of age * subjects, parents/legal guardians must be able to comprehend and read the english language * subjects must have a diagnosis of atopic dermatitis (ad) by a board-certified dermatologist exclusion criteria: * subjects who do not fit the inclusion criteria * subjects unable or unwilling to comply with the study procedures * concurrently have other inflammatory skin conditions * prior known allergies to any components of the materials used * a subject who in the opinion of the investigator will be uncooperative or unable to comply with study procedures * subject unable to speak or read the english language * those that are pregnant, prisoners or cognitively impaired

Keywords: atopic dermatitis eczema
modeling blood management and hemolytic risk in pediatric heart surgery

Conditions: Heart Surgery; Blood Transfusion; Hemolysis

Summary: this study aims to learn more about blood management in children undergoing heart surgery, such as the right amounts, and the best blood products, to administer. it also aims to develop a mathematical model that may help researchers better predict and treat patients who need blood transfusions during heart surgery.


Eligibility criteria:
inclusion criteria: * pediatric patients under 18 years of age undergoing cardiac surgery with clear prime on cardio-pulmonary bypass (cpb) at boston children's hospital (bch). exclusion criteria: * patients with known hemolytic disorders, patients on nitric oxide preoperatively, and patients found to have abnormal coagulation on routine preoperative assessment. patients receiving heparin, american society of anesthesia (asa) status, apixaban, warfarin, or bivalirudin held appropriately (i.e. for elective surgery) will not be excluded
calibration of a new reflectance oximeter.

Conditions: Healthy Volunteer

Summary: this study is about the development of a new medical device for the monitoring of of sleep disordered breathing. this device is developed by the cea-leti-le2s and will be composed of an oximeter, an actimeter in order to measure the activity level of the subject, his state of sleeplessness/sleep, and a co2 partial pressure transcutaneous sensor (ptcco2). developing this device is realized in several steps : a study (almost) is already in progress and its goal is to acquire a database of polysomnography to create automatic algorithms in order to detect respiratory disorders with this device under development. the main goal of the study is to calibrate the oxymeter under development.


Eligibility criteria:
inclusion criteria: * subjects (both gender) aged between 18 to 50 years affiliated to a certain social security, that has given their free consent to participate to the study * subjets without any pathology known and not under medical treatment likely to suffer from controlled hypoxia at levels demanded in the protocol. * subjets having a regular practice of sport exclusion criteria: * subjet non affiliated to a certain social security * smoker or person exposed to passive smoking * history of acute mountain sickness or known sensitivity to hypoxia * any chronic pathology known, in particular pathologies behind high rates of methaemoglobin * pregnant, parturient or breastfeeding women, person deprived of liberty by judicial or administrative decision, person under a legally protected order and could'nt be included in clinical trials (persons mentioned in l1121-5 to l1121-8 of csp). * subjets likely to not be cooperative or respectful of the inherent constraints to study participation.

Keywords: sleep apnea oximeter calibration oxygen partial pressure
contribution of actigraphy and recognition video in apathy assessment of alzheimer's disease : experimental research

Conditions: Alzheimer's Disease

Summary: neuropsychiatric symptoms form part of the clinical picture of alzheimer's disease (ad) and other dementias. irrespective of the severity of the disease, the most frequently encountered symptom is apathy. apathy is increasingly diagnosed in patients with neurological and psychiatric conditions. apathy is a disorder of motivation, defined as "the direction, intensity and persistence of goal-directed behaviour". most of the current descriptions acknowledge this point and consider apathy in terms of a lack of goal-directed behaviour, cognition or emotion. the classical neuropsychiatric symptom assessments are subjective structured interview-based, using input from the caregiver and/or the patient. new technologies are likely to provide us with a more objective measure. an example is ambulatory actigraphy, consisting of a piezoelectric accelerometer designed to record arm movement in three dimensions. the aim of the present study is to assess using actigraphy and video recording signal, ad patients with (n = 15) and without (n = 15) apathy and control subjects (n = 5) during an activity of daily living scenario .


Eligibility criteria:
inclusion criteria: * male or female, \> 65 years ; * alzheimer's disease according to the nincds-adrda criteria (mckhann,drachman et al. 1984) ; * mini mental test examination (mmse) \> 20 ; * no motor anomaly according to updrs iii (tremblements, rigidité musculaire) ; * no depression criteria according to dsm iv-r criteria ; * patient with a cholinergic treatment at dose stable since 3 months ; * patient with social insurance ; * signature of informed consent. exclusion criteria: * neuropsychologics assessment impossible due to sensorial and disrupt ; * prescription of psychotrop treatment (hypnotic, anxiolytic, antidepressant, antipsychotic) in the week previous actigraphy recording.

Keywords: alzheimer apathy actigraphy
dermacyd ph_detinlyn (lactic acid) sweet flower - compatibility

Conditions: Hygiene

Summary: to demonstrate the absence of irritation potential (primary dermical irritability and cumulated dermical irritability) and allergy (sensibilization) of the product dermacyd phdetinlyn sweet flower.


Eligibility criteria:
inclusion criteria: * phototype skin i,ii, iii e iv * integral skin test in the region; * willingness in following the study procedures and to be present in the clinic at the days and scheduled time for medical evaluations and for application of occlusion; exclusion criteria: * lactation or gestation * use of antiinflammatory and/or immunossupression drugs * personnel history of atopy the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial. * history of sensitivity or irritation for topic products; * active cutaneous disease; * use of new drugs or cosmetics during the study the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
observational non-interventional study of febrile neutropenia patients to evaluate antibacterial therapeutical options

Conditions: Febrile Neutropenia

Summary: the purpose of this study was to define and classify antibacterial agents used in turkey for patients with febrile neutropenia.


Eligibility criteria:
inclusion criteria: * patients who are 18 years old and above. * patients who have undergone allogeneic/autologous or peripheral stem cell transplantation following induction or consolidation treatment due to acute hematological malignancy. * patients who have a neutrophil count below 500 cells per cubic millimeter (cells/mm\^3) or below 1000 cells/mm\^3 with an expectancy to rapidly decrease below 500 cells/mm\^3. * patients with a body temperature more than or equal to (≥)38.3 degrees celsius (101 degrees fahrenheit) on single oral measurement or detected ≥38.0 degrees celsius for at least an hour and thus started on antibacterial treatment will be included in the trial. exclusion criteria: - patients who are pregnant or considering pregnancy.

Keywords: antibacterials classification of antibacterial agent febrile neutropenia turkey
biomarkers during pregnancy

Conditions: Diabetes Mellitus in Pregnancy; Gestational Diabetes

Summary: this study aims to obtain preliminary data for utility of alternate biomarkers for monitoring glucose control in diabetic women during pregnancy and/or predicting risk of adverse neonatal events in these women.

this study aims to obtain preliminary data for utility of alternate biomarkers for monitoring glucose control in diabetic women during pregnancy and/or predicting risk of adverse neonatal events in these women. our population is unique compared to published studies and contains significant numbers of african american women and overweight or obese women. two of these markers have been examined in several other populations of pregnant women and have shown utility for both outcomes. however, the recommended levels of these markers need to be determined in specific populations as ethnicity and bmi affect the values. values obtained in recruited women will be compared with biobank samples from women who have no evidence or history of diabetes. additionally, two other potentially promising markers will be examined (beta-hydroxybutyrate and triglycerides). both these analytes change during pregnancy and beta-hydroxybutyrate has shown correlation with large for gestational status or macrosomia in some studies. a combination of markers may be a better predictor of adverse neonatal outcomes than a single marker.

Eligibility criteria:
inclusion criteria: * all women included in the study will either have diabetes diagnosed before pregnancy or will have been diagnosed during pregnancy (gdm). we do not exclude minors, since in missouri, they may consent to medical treatment without parental consent for medical issues relating to pregnancy, exclusion criteria: * no specific exclusion criteria will be used. bmi data will be collected and utilized to sort patients into various subgroups, but will not be used as exclusion criteria.
study of 6(s)-5-mthf among selective serotonin reuptake inhibitor-resistant outpatients with major depressive disorder

Conditions: Depression

Summary: the purpose of the study is to test whether oral 6(s)-5-mthf (deplin) is safe and effective in relieving depression when it is added to standard kinds of antidepressants called serotonin reuptake inhibitors (ssris).

the study consists of two phases, each lasting a total of four weeks (8 weeks total), with visits at the dcrp every 10 days. if the subject is eligible, they will be asked to return two weeks later for a baseline visit, when they will be randomly assigned, like a flip of a coin, to one of three treatment groups: a) drug/drug, b) placebo/drug, c) placebo/placebo (a placebo is a pill that looks like a study drug but contains no active medication). they will have a greater than 50% chance of receiving active medication (deplin) at some point in the 8 week study. neither the subject nor the research staff will know which group the subject is in. all subjects will be asked to take the study medication in the morning, in addition to their ongoing ssri treatment.

Eligibility criteria:
inclusion criteria: * 18-65 years old * meet criteria for current major depressive disorder * currently taking an ssri exclusion criteria: * pregnant women * unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease * prior course of mthf augmentation, or intolerance to mthf at any dose * substance use disorders active within the last six months, any bipolar disorder (current or past), any psychotic disorder (current or past) * have failed more than 2 adequate antidepressant trials during the current major depressive episode

Keywords: depression medical food
impact: improving maternal postpartum access to care through telemedicine

Conditions: Postpartum Complication

Summary: the purpose of this study is to compare two complex, multi-component evidence-based postpartum interventions in underserved populations of lower socioeconomic status in an effort to reduce maternal morbidity and mortality.

this large, multi-center randomized controlled trial will compare two multi-component postpartum care models via hybrid type 1 design conducted in two phases. an initial phase (phase 1) will collect baseline data and ensure patient input into final study. in phase 2, women will be randomized. comparators are evidenced- based approaches: (1) an intensive in-person education with virtual education via push notifications using an electronic health record web portal; (2) a telehealth model using serial encounters. the "push" approach using notifications directly contrasts with the "pull" approach using telehealth visits. both models include home visit programs. the study population includes patients delivering in two urban, inner-city health systems: parkland (dallas, tx) and grady memorial (atlanta, ga). the primary outcome is time from hospital discharge to diagnosis and treatment of a composite of complications in the first 6 weeks. based upon pilot data, 2349 women will demonstrate a 40% reduction (9 to 5.4 days) with 80% power and two-sided alpha of 0.05. 3500 women will be enrolled (1000 in phase 1; 2500 in phase 2) with anticipated \<5% attrition at 6 weeks. inclusion will be women who deliver liveborn infants. secondary outcomes include mental health disorders, emergency room visits, hospital admissions, patient knowledge, quality of life and satisfaction, provider satisfaction, and social determinants of health. women will be followed for one year postpartum.

Eligibility criteria:
inclusion criteria: * postpartum women who deliver a live born infant at parkland hospital or grady health and receive postpartum care at dedicated community clinics. * due to the nature of the study, all will be women, and all will be postpartum, thus of reproductive age. postpartum women 18 years of age and older will be considered for inclusion if informed consent can be obtained. exclusion criteria: * postpartum women who do not deliver at parkland hospital or grady health will not receive postpartum care in the pre-specified community clinics for parkland health systems. * patients with a primary language other than english or spanish.

Keywords: telemedicine hypertension wound infection readmission metritis mastitis maternal mortality postpartum complications
effect of ankascin 568-p products regulating blood lipid

Conditions: Hyperlipidemias

Summary: this study is a randomized, double-blind, placebo-controlled, parallel-controlled trial (24 weeks in total), divided into three periods (screening, treatment, and discontinuation follow-up)

this experiment hopes to understand the effect of long-term consumption of red yeast rice products on blood lipid regulation and high-density lipoprotein cholesterol (hdl-c) elevation and to monitor the changes in the subjects' overall health status. this case is a randomized, double-blind, placebo-controlled trial. it is expected to recruit 80 subjects and randomly assign them to 2 groups to take red yeast rice products or a placebo for 24 weeks. the test group takes one red yeast rice capsule (containing 220 mg ankascin 568-p), the control group took a placebo capsule of similar appearance (containing an equal weight of maltodextrin) every day, and blood samples were collected at 0, 4, and 12, 24, weeks for biochemical analysis and recorded. subjects' general body position measurement, blood pressure, blood lipids, blood sugar and other related changes, and monitoring of liver, kidney, and thyroid function.

Eligibility criteria:
inclusion criteria: * male or female women over the age of 20 (women of childbearing age should not be pregnant or breastfeeding during the study period). * a sane and communicative adult. * 18≦bmi≦35. * sub-healthy people with simple dyslipidemia and those who have been judged by the doctor that they do not need to take hypolipidemic drugs for the time being, or those who insist on not taking drugs. * screening criteria low-density lipoprotein cholesterol (ldl-c): 130\~190 mg/dl. screening criteria and high-density lipoprotein cholesterol (hldl-c): below 50 mg/dl. * those without other serious diseases (cancer, heart failure, diabetes, myocardial infarction, liver cirrhosis, moderate to severe liver and kidney dysfunction, stroke, etc.). * during the experiment, the daily routine and eating habits should be maintained and not changed deliberately. exclusion criteria: * triglyceride tg≧500 mg/dl. * blood pressure value: systolic blood pressure ≧ 200 mmhg or diastolic blood pressure ≧ 140 mmhg. * patients with moderate or severe abnormal liver and kidney function (generally referring to serum aminopyruvate converting enzyme (sgpt), serum glutamate phenylacetate transaminase (sgot) are more than 3 times the upper limit of normal or have been diagnosed liver cirrhosis, or glomerular filtration rate egfr≦30 ml/min/1.73m2). * pregnant or lactating women. * those who take traditional chinese medicine mainly based on red yeast rice. * those who have undergone surgery within one month. * those who have serious diseases such as heart, liver, kidney, and hematopoietic system, mentally ill patients who do not meet the inclusion criteria, fail to use the test product according to the regulations so that the efficacy or safety cannot be judged due to incomplete data.
disease-related fatigue monitoring based on body signals measured on the skin

Conditions: Post-COVID-19 Related Fatigue

Summary: this study investigates the use of physiological parameters as predictors of disease-related fatigue. for that purpose, wearable devices are used to monitor post-covid-19 patients during their stay in a rehabilitation clinic. besides, the effectiveness of respiratory training in reducing breathlessness and improving exercise breathing patterns in patients suffering from post-covid-19 will be explored.


Eligibility criteria:
inclusion criteria: * adults (≥18 years old) * suffering from post-covid-19 fatigue (i.e., score equal or higher than 5 on the single-item fatigue \[sif\] or the fatigue severity scale \[fss\]) * admitted to gais rehabilitation clinic * able to use a mobile phone * able to wear and handle the monitoring devices exclusion criteria: * patients suffering from a relevant comorbidity (i.e., comorbidity resulting in significant distortion of physiological signals \[e.g., moderate to severe chronic obstructive pulmonary disease or persistent atrial fibrillation\]) * pregnancy * unable to use, wear or handle the monitoring systems

Keywords: self-reported fatigue fatigue questionnaires continous monitoring of physiological signals predictive model for fatigue condition respiratory training